Alcoholic hepatitis: Prognosis and treatment

Gastroenterologia y Hepatologia

Volumn 37, Issue 4, 2014, Pages 262-268

  Casanova, Jennifer ^a   Bataller, Ramón ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholic liver disease; Clinical guidelines; Liver transplantation

Indexed keywords

ALCOHOL; PENTOXIFYLLINE; PREDNISOLONE; DRUGS USED IN THE TREATMENT OF ADDICTION; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; S ADENOSYLMETHIONINE; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALCOHOLIC HEPATITIS HISTOLOGICAL SCORE; ARTICLE; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; NONHUMAN; PROGNOSIS; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT INDICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIET THERAPY; DISEASE MODEL; FATTY LIVER, ALCOHOLIC; HEPATITIS, ALCOHOLIC; INCIDENCE; LIVER; LIVER FAILURE; MALNUTRITION; MORTALITY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ALCOHOL DETERRENTS; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FATTY LIVER, ALCOHOLIC; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; MALNUTRITION; PENTOXIFYLLINE; PREDNISOLONE; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; S-ADENOSYLMETHIONINE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898821633     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2014.02.001     Document Type: Article

References (58)

1. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011, 141:1572-1585.
2. Roulot D., Costes J.L., Buyck J.F., et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011, 60:977-984.
3. Altamirano J., Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 2011, 8:491-501.
4. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. N Engl J Med 2009, 360:2758-2769.
5. Sandahl T.D., Jepsen P., Thomsen K.L., Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. J Hepatol 2011, 54:760-764.
6. Naveau S., Giraud V., Borotto E., Aubert A., Capron F., Chaput J.C. Excess weight risk factor for alcoholic liver disease. Hepatology 1997, 25:108-111.
7. Kryger P., Schlichting P., Dietrichson O., Juhl E. The accuracy of the clinical diagnosis in acute hepatitis and alcoholic liver disease. Clinical versus morphological diagnosis. Scand J Gastroenterol 1983, 18:691-696.
8. Mookerjee R.P., Lackner C., Stauber R., et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011, 55:1103-1111.
9. Ramond M.J., Poynard T., Rueff B., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512.
10. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012, 57:399-420.
11. Maddrey W.C., Boitnott J.K., Bedine M.S., Weber F.L., Mezey E., White R.I. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
12. Carithers R.L., Herlong H.F., Diehl A.M., et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989, 110:685-690.
13. Dominguez M., Rincon D., Abraldes J.G., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008, 103:2747-2756.
14. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41:353-358.
15. Forrest E.H., Evans C.D., Stewart S., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54:1174-1179.
16. Srikureja W., Kyulo N.L., Runyon B.A., Hu K.Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005, 42:700-706.
17. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45:1348-1354.
18. Mathurin P., O'Grady J., Carithers R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011, 60:255-260.
19. Altamirano J., Fagundes C., Dominguez M., et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2012, 10:65-71. e3.
20. Altamirano J., Miquel R., Katoonizadeh A., et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014, [in press].
21. Helman R.A., Temko M.H., Nye S.W., Fallon H.J. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971, 74:311-321.
22. O'Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology 2010, 51:307-328.
23. Imperiale T.F., McCullough A.J. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990, 113:299-307.
24. Rambaldi A., Saconato H.H., Christensen E., Thorlund K., Wetterslev J., Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008, 27:1167-1178.
25. Louvet A., Wartel F., Castel H., et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009, 137:541-548.
26. Kendrick S.F., Henderson E., Palmer J., Jones D.E., Day C.P. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology 2010, 52:126-131.
27. Louvet A., Diaz E., Dharancy S., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008, 48:465-470.
28. Akriviadis E., Botla R., Briggs W., Han S., Reynolds T., Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
29. De B.K., Gangopadhyay S., Dutta D., Baksi S.D., Pani A., Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15:1613-1619.
30. Whitfield K., Rambaldi A., Wetterslev J., Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009, CD007339.
31. Colmenero J., Bataller R., Sancho-Bru P., et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007, 132:687-697.
32. Dominguez M., Miquel R., Colmenero J., et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009, 136:1639-1650.
33. Spahr L., Rubbia-Brandt L., Frossard J.L., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002, 37:448-455.
34. Naveau S., Chollet-Martin S., Dharancy S., et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004, 39:1390-1397.
35. Boetticher N.C., Peine C.J., Kwo P., et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008, 135:1953-1960.
36. Cabre E., Rodriguez-Iglesias P., Caballeria J., et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
37. Foody W., Heuman D.D., Mihas A.A., Schubert M.L. Nutritional therapy for alcoholic hepatitis: new life for an old idea. Gastroenterology 2001, 120:1053-1054.
38. Stickel F., Hoehn B., Schuppan D., Seitz H.K. Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003, 18:357-373. [Review article].
39. Lu S.C., Martinez-Chantar M.L., Mato J.M. Methionine adenosyltransferase and S-adenosylmethionine in alcoholic liver disease. J Gastroenterol Hepatol 2006, 21(Suppl. 3):S61-S64.
40. Mato J.M., Camara J., Fernandez de Paz J., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999, 30:1081-1089.
41. Rambaldi A., Gluud C. S-adenosyl-l-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006, CD002235.
42. Burra P., Senzolo M., Adam R., et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010, 10:138-148.
43. Stickel F., Seitz H.K. Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2010, 24:683-693.
44. Dureja P., Lucey M.R. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol 2010, 52:759-764.
45. Rambaldi A., Iaquinto G., Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am J Gastroenterol 2002, 97:1674-1681.
46. Fede G., Germani G., Gluud C., Gurusamy K.S., Burroughs A.K. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2011, CD002800.
47. Pares A., Planas R., Torres M., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998, 28:615-621.
48. Mezey E., Potter J.J., Rennie-Tankersley L., Caballeria J., Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004, 40:40-46.
49. Nguyen-Khac E., Thevenot T., Piquet M.A., et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011, 365:1781-1789.
50. Addolorato G., Mirijello A., Leggio L., Ferrulli A., Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013, 27:287-299.
51. Krampe H., Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010, 16:2076-2090.
52. Forns X., Caballeria J., Bruguera M., et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol 1994, 21:853-857.
53. Anton R.F. Naltrexone for the management of alcohol dependence. N Engl J Med 2008, 359:715-721.
54. Anton R.F., O'Malley S.S., Ciraulo D.A., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. J Am Med Assoc 2006, 295:2003-2017.
55. Rosner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, CD004332.
56. Addolorato G., Leggio L., Ferrulli A., Caputo F., Gasbarrini A. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 2009, 18:675-686.
57. Johnson B.A., Rosenthal N., Capece J.A., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. J Am Med Assoc 2007, 298:1641-1651.
58. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.